Value Creation Approach
FIRM HISTORY
Consistent focus on DACH lower mid-market buyouts
GEP 1- €80m - 1996
(liquidated)
ECM
GEP II - €125m - 1999
(liquidated)
GEP III - €250m - 2006
(to be liquidated)
GEP IV - €230m - 2012
(current)
Investment Period: 1996-1999
Platform investments: 6
Add-ons: 6
Agg. Revenue growth: 52%1
Agg. EBITDA growth: 52%1
Status: Liquidated
Vestas
Investment Period: 1999-2005
Platform investments: 8
Add-ons: 4
Agg. Revenue growth: 9%1
Agg. EBITDA growth: 58%¹
Status: Liquidated
PAALGROUP
SPECTRO
MAREDO
ALUKON
SYSTEM
Investment Period: 2006-2012
Platform investments: 5
Add-ons: 2
Agg. Revenue growth: 4%1
Agg. EBITDA growth: 26%1
Status: Liquidation 2018
SODA
SODAWERK STASSFURT
IN ZIME
EXPRESS LOGISTIK
Investment Period: 2012-2018
Platform investments: 7
Add-ons: 4
Agg. Revenue growth: 26%¹
Agg. EBITDA growth: 43%1
Status: In investment phase
BERGMANN
LED NER
MEDIFOX
care management software
MAP ARZT UND PATIENT
MEDIZINTECHNIK FÜR
CINE MEDIA
FILM AG
eismann
Aktiengesellschaft
Kühnle, Kopp & Kausch
MAREDO
polytan
KADI
CASA REHA
Unternehmensgruppe
titus AG
M&J Fibretech als
polycomp
Kamps
DERMATOLOGIKUM
HAMBURG
WIENERS+WIENERS
Translation Adaptation Proofreading
uroviva
SPEZIALISTEN FÜR UROLOGIE
ALBRECHT & DILL
HAMBURG-EST 1960
Note: For illustrative purposes only. Data as of 28 February, 2018. Investors are reminded that past performance is not a reliable indicator of future results. See Important Information on page 1 and
further detail on investment performance and information related to investment performance on pages 15 and 20. (1) Source: ECM. Based on ECM's internal methodology, assumptions and views.
Based on aggregated revenues and EBITDA for all investments in the respective funds. Does not adjust for inorganic growth through add-on acquisitions. Data as of 30 September, 2017. Excludes
Uroviva, which closed in December 2017, and Albrecht & Dill, which closed in February 2018.
3/21View entire presentation